NCT00366600已完成1 期
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Healthy Subjects.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 2
- 主要终点
- Pharmacokinetics; safety and tolerability; influence of food on the same.
研究概览
简要总结
Safety and tolerability of HKI-272 in healthy subjects; the influence of food intake on the same.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Pharmacokinetics; safety and tolerability; influence of food on the same.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study Evaluating SKI-606 Administered to Healthy SubjectsHealthyNCT00406406Wyeth is now a wholly owned subsidiary of Pfizer
已完成
1 期
A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid TumorsTumorsNCT00397046Puma Biotechnology, Inc.21
已完成
1 期
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy SubjectsDiabetic NephropathyNCT05492630Sunshine Lake Pharma Co., Ltd.138
已完成
1 期
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast CancerAdvanced Malignant Solid TumorsBreast NeoplasmsAdvanced Breast CancerNCT00445458Puma Biotechnology, Inc.110
已完成
1 期
A HR20031 FE Study on Healthy SubjectsType 2 DiabetesNCT05692934Shandong Suncadia Medicine Co., Ltd.40